Psychiatric Diagnosis is Meaningless

Posted on August 26, 2024 by cchrstl

The most recent psychiatric billing bible, providing the official diagnoses that can be used for insurance reimbursements, is The Diagnostic and Statistical Manual of Mental Disorders (DSM-5-TR, Text Revision of 2022).

Diagnostic categories within the DSM are heterogeneous. Diagnostic heterogeneity is the idea that diagnostic labels can capture different syndromes with different causes under the same heading.
[Heterogeneous = Made up of elements that are not alike.]

For example, there are almost 24,000 possible combinations of symptoms for panic disorder in DSM-5, making it extremely difficult to assign any specific cause to the condition; and thus making it extremely difficult to confidently recommend any particular treatment. Two different people could receive the same diagnosis without sharing any common symptoms, meaning that the category “Panic Disorder” is scientifically meaningless.

You can see that such diagnostic heterogeneity is problematic for both research and clinical practice.

We refer to the research paper “Heterogeneity in psychiatric diagnostic classification“, by Allsopp, Read, Corcoran, and Kinderman (published 3 July 2019).

The study concludes that psychiatric diagnoses are scientifically worthless as tools to identify discrete mental health disorders. Lead researcher Dr. Kate Allsopp, University of Liverpool, said: “Although diagnostic labels create the illusion of an explanation they are scientifically meaningless and can create stigma and prejudice.”

Psychiatrists excuse this lack of rigor by saying it allows for “clinical judgment.”

In point of fact, such “judgment” is worthless, as it relies upon opinions. What is the alternative? Since there are no clinical tests for these fraudulent psychiatric diagnoses, the correct action on a mentally disturbed person is a full searching clinical examination by a competent non-psychiatric health care practitioner, in order to find and treat any undiagnosed and untreated real medical conditions.

Posted in Big Muddy River Newsletter | Tagged , | Comments Off on Psychiatric Diagnosis is Meaningless

CCHR Commends FDA Decision: Psychedelic Drug Ecstasy Not Proven Safe or Effective Treatment for Traumatized Patients

Posted on August 19, 2024 by cchrstl

The U.S. drug regulatory agency examined evidence presented by the company requesting approval for MDMA (ecstasy) and reports from experts examining that evidence before denying approval for the drug as mental health treatment. A medical journal has just retracted three MDMA therapy research papers for ethical violations.

by CCHR National Affairs Office

The U.S. Food and Drug Administration (FDA) has rejected the psychedelic drug MDMA, commonly known as ecstasy or molly, as treatment for post-traumatic stress, a decision that Citizens Commission on Human Rights (CCHR) advocated in its statement submitted to the FDA during a public comment period earlier this year. The FDA’s decision ends the first attempt to gain the agency’s approval for a psychedelic drug treatment.

The FDA concurred with the findings of its advisory committee of independent experts, which held a public hearing in June on the use of MDMA for psychedelic-assisted psychotherapy. The committee voted overwhelmingly that the company which applied for drug approval, Lykos Therapeutics, failed in its clinical trials to prove the treatment was effective, and that benefits from the drug therapy did not outweigh the risks.

A briefing document prepared by FDA staff and issued prior to the hearing pointed to a number of drawbacks in the data from the Lykos clinical trials. Claims of efficacy could be skewed by a large majority of trial participants knowing whether they had received MDMA or placebo, the staff observed. The cardiovascular risks of MDMA, which acts as a stimulant, and the underreporting of adverse effects were also concerns. 

During the hearing, committee members discussed allegations of ethical misconduct in the clinical trials, including claims that participants were pressured not to report adverse effects. The Wall Street Journal recently reported that three people participating in the Lykos clinical trials felt more suicidal during or after the testing, but felt pressured to report positive outcomes. Their adverse effects were not reflected in the research results.

Another patient was allegedly sexually assaulted by the two psychotherapists who stayed in the room with her as part of the MDMA treatment. MDMA is known to lower inhibition and increase sexual desire.  Nese Devenot, a researcher at Johns Hopkins University who petitioned the FDA to hold the public hearing, told NPR that psychotherapy with a patient on MDMA “incentivized boundary violations.”

In June, ahead of the advisory committee hearing, the Institute for Clinical and Economic Review, an independent research organization that reviews health care interventions, issued a report that also was critical of the Lykos clinical trial data and results, concluding there was insufficient evidence to support approval of the MDMA treatment.

Additionally, Lykos was criticized by advisory committee members for the failure to follow the instructions, or protocol, for conducting its studies. Shortly after the FDA’s decision, the journal Psychopharmacology retracted three research papers it had published about MDMA-assisted psychotherapy due to “protocol violations amounting to unethical conduct” during the clinical trials. Many of the authors of the papers are reportedly affiliated with Lykos.

The FDA also had to contend with the fact that it regulates drugs, but cannot regulate the psychotherapy component of the proposed treatment. 

The FDA’s decision not to approve this use of MDMA with psychotherapy was made despite massive lobbying by the psychopharmaceutical industry.  Companies developing psychedelic drugs for therapy have attracted millions of dollars from investors hoping to cash in on a “psychedelic revolution.”  Some veteran groups also advocated for approval because existing psychiatric drugs and practices have failed to handle veterans’ mental health issues. 

“The FDA is commended for not caving in to the psychopharmaceutical industry’s pressure for approval of MDMA-assisted psychotherapy when safety and efficacy of the drug have not been established,” said Anne Goedeke, president of the CCHR National Affairs Office. “Psychedelic drugs are being pushed because psychiatric drugs and practices have failed to handle the mental health issues of many traumatized veterans; but our veterans deserve better treatment than the risk of further damage to their mental health from a use of psychedelics that has not proven safe or effective.”

Posted in Big Muddy River Newsletter | Tagged , , , , | Comments Off on CCHR Commends FDA Decision: Psychedelic Drug Ecstasy Not Proven Safe or Effective Treatment for Traumatized Patients

At 988 Crisis Lifeline’s Second Anniversary, CCHR Calls on SAMHSA to Provide Data to Researchers for Evaluation of Effectiveness, Outcomes

Posted on August 12, 2024 by cchrstl

The Substance Abuse and Mental Health Services Administration should make 988 Lifeline data available so researchers and policymakers can evaluate the effectiveness and appropriateness of the handling of calls, and to ensure callers’ human rights are being respected, Citizens Commission on Human Rights says.

by CCHR National Affairs Office

Citizens Commission on Human Rights (CCHR) is calling on the U.S. Substance Abuse and Mental Health Services Administration (SAMHSA) to collect and make publicly available data from the 988 Suicide and Crisis Lifeline on the reasons for calls to the Lifeline and the resolutions of those calls, so that researchers and policymakers have an accurate picture of the results of the program. 

In particular, CCHR is concerned with evidence of a growing rate of distressed or unhappy callers having police, emergency medical teams, or mobile behavioral health crisis units show up unexpectedly at their location to transport them against their will to psychiatric facilities for evaluation, a procedure that may be considered a violation of human rights under international human rights standards.  What’s more, research shows that coercive practices do not reduce, but increase the likelihood of future suicide attempts.

The 988 Lifeline system, formerly known as the National Suicide Prevention Lifeline, launched in July 2022 to provide an individual in crisis, or someone connected to them, a phone number to call and get help with their mental health or substance abuse issue. 

The statistics publicly available from Vibrant Emotional Health, the national Lifeline administrator, and SAMHSA do not include either the circumstances that led to the calls, which can be non-emergency in nature, or the outcomes for the callers, so it is not known how many calls end up with the caller receiving the emergency intervention of being involuntarily transported by police or emergency medical teams to psychiatric facilities, or why.

Vibrant’s stated policy is to “initiate an involuntary emergency service intervention only as a last resort,” and it has long reported that one in 50 (2%) of calls to the Lifeline lead to emergency services being dispatched.

However, there is evidence from states’ reports on their own call centers and from NRI, a nonprofit organization that collects data on public behavioral health systems, that this figure may significantly understate the number of Lifeline callers being subjected to coercive emergency procedures.

In its 2023 report on various outcomes from crisis call centers in 10 to 25 states, NRI found that “an average of 16.9% of calls (median of 7.0%) resulted in mobile crisis [teams] being dispatched, 3.8% resulted in law enforcement being dispatched, 1.9% resulted in EMS [emergency medical services] being dispatched, and 2.3% of calls were transferred to a 911 system (which may have then dispatched law enforcement or EMS to respond to the individual in crisis).”

Research has found that forcing people to go to psychiatric facilities does not improve mental health outcomes and that those admitted against their will are more likely to attempt suicide after discharge. Concern about being involuntarily confined in a psychiatric setting is one of the main reasons young people do not seek mental health care.

In light of evidence showing a lack of benefit and considerable harm from coercive mental health treatment, international human rights organizations are calling for abolishing all coercive mental health practices. In 2023, the World Health Organization (WHO) and the United Nations Office of the High Commissioner for Human Rights called for an end to coercive mental health services, saying the practices “violate the right to be protected from torture or cruel, inhumane and degrading treatment.” 

WHO’s opposition to nonconsensual mental health treatment extends even to those in acute mental distress, saying that individuals in mental health crisis “are at a heightened risk of their human rights being violated, including through forced admissions and treatment,” which are “harmful to people’s mental, emotional and physical health, sometimes leading to death.”

In 2019, the Council of Europe passed a resolution calling on its member nations “to immediately start to transition to the abolition of coercive methods in mental health settings.” The resolution cited evidence pointing to the “overwhelmingly negative experience of coercive measures, including pain, trauma and fear.”

Among international psychiatric organizations, the World Psychiatric Association has stated its concern about “the extent to which coercive interventions violate” human rights. The European Psychiatric Association says that examining how to reduce coercive practices in psychiatry is a priority for the association. 

However, the American Psychiatric Association has refused to reverse its position in support of involuntary psychiatric treatment.  CCHR has called on the association to renounce coercive psychiatric practices and align with international human rights standards.

Since its founding in 1969, Citizens Commission on Human Rights has worked to restore human rights and dignity to the field of mental health.  It has advocated for widespread adoption of a Mental Health Declaration of Human Rights that lays out fundamental human rights in the field of mental health.

In its April 2024 report on the 988 Lifeline, SAMHSA says that it will “strengthen data collection from [call] centers to assess outcomes of service.” SAMHSA acknowledges that no research has yet shown a reduction in near-term suicide risk from the Lifeline.

“SAMHSA owes the American people transparency on the results of the 988 hotline,” says Anne Goedeke, president of the CCHR National Affairs Office. “Making meaningful data from this massive program available to policymakers and independent researchers to evaluate should be a priority for SAMHSA.”

Posted in Big Muddy River Newsletter | Tagged , , , , , , , , | Comments Off on At 988 Crisis Lifeline’s Second Anniversary, CCHR Calls on SAMHSA to Provide Data to Researchers for Evaluation of Effectiveness, Outcomes

CCHR Calls for Congressional Action to End Use of Restraints in Mental Health Treatment

Posted on August 5, 2024 by cchrstl

Citing a new report on the success of no-restraint policies in Italy, Citizens Commission on Human Rights calls for mental health care reforms that align with international standards for a human rights-based approach in mental health practices.

by CCHR National Affairs Office 

A new report details the success of an initiative in Italy to safeguard the human rights of psychiatric patients by ending the use of restraints in some of the country’s hospital psychiatric wards. Citizens Commission on Human Rights (CCHR) calls on Congress to take long overdue action towards eliminating restraints, as well as seclusion, forced drugging and other coercive psychiatric practices in the U.S., aligning with international standards to protect and ensure human rights in mental health care. 

Italian researchers investigated the results of no-restraint policies in 24 Italian hospital psychiatric units, which had an average of 13 beds per unit. The country’s no-restraint initiative calls for no use of restraints and no locked doors leading into the ward. Restraints are belts or straps used to restrict a person’s movement, typically by strapping them to a bed or table.

Researchers found that 14 of the 24 units reported no use of restraints during 2022, while the other 10 units used restraints an average of just 4.5 times during the year and committed to eliminating the use completely. Two-thirds (63%) of the units operated with no locked access doors to the unit. Patients were allowed to keep personal items such as telephones and computers.

“This research adds empirical weight to the advocacy for restraint-free environments in mental health settings, signaling a paradigm shift toward more humane and rights-respecting” care, the researchers wrote.

In 2023, the World Health Organization (WHO) and the United Nations Office of the High Commissioner for Human Rights called for an end to all forced mental health treatment, saying coercive practices “violate the right to be protected from torture or cruel, inhumane and degrading treatment.”

Earlier guidance from WHO in 2021 stated that coercive mental health treatment should end even for those experiencing acute mental distress, pointing out that individuals in mental health crisis “are at a heightened risk of their human rights being violated, including through forced admissions and treatment,” which “have been shown to be harmful to people’s mental, emotional and physical health, sometimes leading to death.”

Earlier still, the Council of Europe in 2019 adopted a resolution that called on its member nations “to immediately start to transition to the abolition of coercive methods in mental health settings.” The resolution cited evidence pointing to the “overwhelmingly negative experience of coercive measures, including pain, trauma and fear.”

Among international psychiatric organizations, the World Psychiatric Association has stated its concern about “the extent to which coercive interventions violate” human rights, and the European Psychiatric Association has said that examining how to reduce coercive practices in psychiatry is a priority for the association.

In contrast, the American Psychiatric Association has maintained its position in support of involuntary psychiatric practices, despite the traumatic impact the practices can have on patients’ emotional well-being and self-worth.

“It is urgent that Congress investigate the harm from the forced psychiatric treatment of vulnerable Americans experiencing mental health issues,” said Anne Goedeke, president of the CCHR National Affairs Office. “Congress must take the lead on needed reforms in the U.S. mental health system, since the American Psychiatric Association has proven unwilling to change its position on its coercive practices to align with international standards for human rights-based mental health treatment.”

Posted in Big Muddy River Newsletter | Tagged , , , , | Comments Off on CCHR Calls for Congressional Action to End Use of Restraints in Mental Health Treatment

New Government Report Provides Fresh Evidence of Racism Entrenched in U.S. Mental Health Services

Posted on July 29, 2024 by cchrstl

African Americans receiving mental health services are disproportionately assessed with disruptive, defiant and psychotic disorders, evidence of the systemic racism that psychiatric and psychological associations admit is ingrained in mental health practices. Citizens Commission on Human Rights alerts the Black community to this reality.

by CCHR National Affairs Office

African Americans are more likely to receive mental health assessments of psychiatric disorders related to disruptive, defiant and psychotic behavior than other racial and ethnic groups, according to data in a newly released government report on Americans’ use of mental health services.  Citizens Commission on Human Rights (CCHR) is alerting the Black community to this fact during Minority Mental Health Awareness Month.

Psychiatrists, psychologists, and other mental health practitioners disproportionately labeled African Americans with attention-deficit hyperactivity disorder (ADHD), schizophrenia, conduct disorder, and oppositional defiant disorder (ODD) in mental health programs operated or funded by state mental health agencies, a 2024 annual report from the U.S. Substance Abuse and Mental Health Services Administration (SAMHSA) shows.  The report used data collected in 2022.

African Americans comprise 33% of the individuals diagnosed with schizophrenia or other psychotic disorders and 20% of those diagnosed with ADHD – significantly higher than their proportion (14%) of the U.S. population.

While African American children aged 0 to 17 years comprised 18% of all children receiving mental health services from state agencies, they represented 24% of children diagnosed with ADHD, 26% of children diagnosed with oppositional defiant disorder, and 27% of children diagnosed with conduct disorder.

The most frequent mental health diagnosis for Black children was ADHD, with the label given to four of every ten (38%) of them.

The report also calls into question any claims by mental health organizations that African American communities are underserved.  While African Americans comprise 14% of the U.S. population, they accounted for 19% of individuals receiving services from state mental health agencies, which suggests that Blacks are overly diagnosed with psychiatric disorders.

An assignment of a psychiatric disorder by psychiatrists and other mental health practitioners is subjective and unscientific.  Psychiatrist Thomas Insel, M.D., former director of the National Institute of Mental Health (NIMH), publicly admitted in 2013 that psychiatry’s “diagnoses” lack validity.  With no scientific basis for the diagnoses, the systemic racism now acknowledged to exist in psychiatric and psychological practice can creep into the assessment of a patient’s behavior as a mental disorder. 

Systemic racism was admitted in a public apology in 2021 by the American Psychiatric Association (APA), in which the APA admitted that psychiatrists’ “appalling past actions, as well as their harmful effects, are ingrained in the structure of psychiatric practice.” 

The American Psychological Association issued its own public apology in 2021, acknowledging the role of psychologists “in promoting, perpetuating, and failing to challenge racism, and the harms that have been inflicted on communities of color as a result.”

Further evidence of ongoing racism in the mental health system is found in recent research revealing that Black psychiatric patients were nearly twice as likely to be physically, mechanically, or chemically restrained in psychiatric facilities than their White counterparts and to remain restrained for a longer time.

Since its founding in 1969 as a human rights organization and mental health industry watchdog, the Citizens Commission on Human Rights has exposed and campaigned against racism and racial abuse in the mental health system.  CCHR intensified its efforts in 2020 by establishing the CCHR Task Force Against Psychiatric Racism and Modern-Day Eugenics, led by Rev. Fred Shaw, Jr.  CCHR has worked with the NAACP since 2003 in exposing the stigmatizing labeling and drugging of African American children and, with Rev. Shaw, in obtaining two national resolutions from the NAACP and one from the National Caucus of Black State Legislators related to these issues.

Posted in Big Muddy River Newsletter | Tagged , , , , , | Comments Off on New Government Report Provides Fresh Evidence of Racism Entrenched in U.S. Mental Health Services

CCHR Commends Congressional Action to Prevent Continued Use of Electrical Shocking Device

Posted on July 22, 2024 by cchrstl

Citizens Commission on Human Rights advocates banning an electrical shocking device used on autistic and disabled students at a Massachusetts institution. Congress removed wording from a current bill that would have allowed shocking to continue after an expected FDA ban of the device.

by CCHR National Affairs Office

A provision in a congressional bill that would have allowed continued use of an electrical shocking device on autistic and disabled students, even if the FDA bans the device, has been removed from the bill.  Citizens Commission on Human Rights (CCHR) commends the members of Congress who removed the provision. 

For years, CCHR has been active in efforts to ban the painful electrical shocking device, used for behavioral conditioning at the Judge Rotenberg Center (JRC), an institution for autistic and disabled students near Boston.  JRC staff administer painful electrical shocks to cause changes in behavior, with electrodes attached to the arm or leg of a student who wears a battery in a backpack.

The FDA previously attempted to ban the device, but JRC prevailed in federal appeals court with a finding that the FDA did not have proper authority over the particular use of the device at JRC.  In 2023, Congress passed legislation that gave the FDA the needed authority. 

Earlier this year, the FDA again started the rulemaking process to ban the device. In its proposed ban, the FDA wrote, “These devices present a number of psychological risks including depression, anxiety, worsening of underlying symptoms, development of post-traumatic stress disorder, and physical risks such as pain, burns, and tissue damage.”

Massachusetts Governor Maura Healey’s administration reportedly has told the FDA that they support the ban.

The bill provision, now removed, would have allowed JRC to continue to use the device if a judge signed a court order approving it for a student.  Since the students being shocked at JRC are under court orders, the expected FDA ban would have been ineffective in stopping use of the device.

The autistic community, disability rights groups, and human rights organizations, including CCHR, conducted a grassroots campaign to brief members of Congress on the physical and psychological harm of the electrical shocking device and to register opposition to the bill loophole.  The groups have vowed to continue to oppose any further efforts to insert language that would allow JRC to get around the expected FDA ban of the shocking device.

Posted in Big Muddy River Newsletter | Tagged , , | Comments Off on CCHR Commends Congressional Action to Prevent Continued Use of Electrical Shocking Device

CCHR Applauds California Supreme Court Decision Holding Electroshock Machine Manufacturer Liable for Brain Damage

Posted on July 15, 2024 by cchrstl

Court concluded that company’s failure to fully disclose risks of electroshock to a physician meant that the patient also did not know the risks before undergoing the procedure, which resulted in brain damage. Citizens Commission on Human Rights warns device has never been proven safe.

by CCHR National Affairs Office

The California Supreme Court has issued a decision in a product liability case involving an electroshock machine which establishes that patients must receive adequate disclosure of the risks of the device prior to treatment. Citizens Commission on Human Rights (CCHR) says electroshock has never been proven safe and has known risks that include brain damage and permanent memory loss.

The lawsuit at issue concerned Somatics LLC, manufacturer of a device used by psychiatrists to deliver electroconvulsive therapy (ECT, or electroshock) to patients who may be experiencing deep depression. The electroshock machine sends a strong electrical current through brain tissue that causes convulsions, a procedure used as treatment even though it is not known how electroshock is supposed to work. Somatics was sued by a woman who had sustained brain damage from ECT treatment.

According to Wisner Baum, the law firm representing the plaintiff, Somatics “did not dispute in the lower court that its electroshock therapy (ECT) device can cause brain damage and permanent memory loss; did not dispute it failed to warn doctors of the risk of brain damage and permanent memory loss; and did not dispute that plaintiff…sustained brain injury.” 

Somatics relied for its defense on legal precedent which had established that device manufacturers have a duty to warn physicians of the risks associated with their products but need not warn the patient of those risks.  The company presented testimony that even if it had given the physician a stronger warning, the physician still would have recommended electroshock to his patient.

However, in its ruling, California’s highest court wrote that a patient’s expectations about the effects of a medical device are based on what their physicians tell them, and without adequate disclosure of risks to the physician, the physician could not give adequate disclosure to the patient. The court concluded that patients could prevail in establishing product liability “by showing that the physician would have communicated the stronger warning to the patient and an objectively prudent person in the patient’s position would have thereafter declined the treatment,” even if the doctor continued to recommend the treatment.

“This California ruling is a win for patients who have a right to know the full extent of the potential damage from electroshock,” said Anne Goedeke, president of the CCHR National Affairs Office. “Patients should be informed that electroshock has never been proven safe or effective.”

Patients undergoing electroshock – mostly women and the elderly, but even young children – are often not being given enough information about the serious risks and lack of effectiveness of the procedure, according to professor of psychology John Read, Ph.D., who conducted an audit of patient information pamphlets.

He found that pertinent information about risks was omitted, such as the cardiovascular risks, the risk of death, the lack of evidence of long-term benefits, and the fact that it is not known how ECT is supposed to work. “The minimisation of risks is not uncommon in ECT practice and research,” Read said. 

Read disputes claims that electroshock is highly effective, writing that no proof of that exists. “There have…been no placebo-controlled studies of ECT for depression since 1985, and all 11 studies prior to that date were very small, severely flawed and conducted on adults,” he wrote, adding, “There have been no placebo-controlled studies on children or adolescents.” 

The U.S. Food and Drug Administration (FDA) requires ECT machines to have signs next to them stating, “The long-term safety and effectiveness of ECT treatment has not been demonstrated,” Read observed.

The Citizens Commission on Human Rights advocates a total ban of electroshock.  More than 135,000 people have signed CCHR’s online petition to ban ECT.

Posted in Big Muddy River Newsletter | Tagged , , , | Comments Off on CCHR Applauds California Supreme Court Decision Holding Electroshock Machine Manufacturer Liable for Brain Damage

New Research Links Psychiatric Hospitalization to Much Higher Risks of Premature Death and Suicide After Discharge, CCHR Warns

Posted on July 8, 2024 by cchrstl

A growing body of evidence suggests that psychiatric hospitalization itself may be a major risk factor for suicide and other harms to patients’ mental health, especially for those admitted against their will. Citizens Commission on Human Rights is calling on Congress to investigate.

by CCHR National Affairs Office

Patients discharged from psychiatric hospitalization face a risk of premature death eight times higher than in the general population, and a risk of suicide 33 times higher, with an even greater risk of suicide – 54 times higher – in the first year after discharge, a new study has found.  The study adds to a growing body of evidence indicating that psychiatric hospitalization does not decrease, but can actually increase the risk of suicide and other harmful outcomes for patients, especially for those receiving treatment against their will. 

Researchers in Spain, Norway and the United States examined medical records of over 49,000 psychiatric patients in Spain who had received psychiatric hospitalization from 2014-2018.  They found that in a follow-up period of one to six years after discharge, 1 in 20 patients (5%) died prematurely (before the age of 70), with the risk of premature death almost eight times higher than in the general population. 

Of even greater concern is the finding that 1 in 10 (10%) committed acts of self-harm, including attempted suicide, after discharge from psychiatric hospitalization, while 1 in 100 (1%) died from suicide.  The risk of suicide was 33 times greater than in the general population during the study’s follow-up period, with an even higher 54 times greater risk in the first year post-discharge.

The study findings indicate that “individuals discharged from psychiatric inpatient care are a vulnerable population for premature death and suicidal behavior,” wrote lead researcher Philippe Mortier, Ph.D., at the Hospital del Mar Research Institute in Barcelona, Spain.  The study was published in JAMA Psychiatry.

Almost 1 in 4 (24%) of the patients hospitalized during the period under study had prior psychiatric hospitalizations, another indication of the inadequacy of psychiatric treatment.

These findings are consistent with other studies which have found that admission to a psychiatric facility is highly associated with the risk of dying from suicide.  A study earlier this year pinpointed the first few days and weeks after discharge as a period of extremely high risk of suicide for patients who received psychiatric hospitalization for depression.  Even many years after discharge, previously hospitalized psychiatric patients have high suicide rates compared to the general population, another study found.

People admitted to a psychiatric facility against their will are even more likely to attempt suicide after discharge than psychiatric patients who were not forcibly admitted, according to research findings.

Antidepressants and other psychiatric drugs used as treatment during hospitalization are also linked to suicidal behavior.  Researchers conducting a 2019 re-analysis of safety summaries in the U.S. Food and Drug Administration (FDA) database found evidence that depressed patients receiving antidepressants attempted suicide at a rate 2.5 times higher than those who received a placebo.

“With substantial evidence that psychiatric hospitalization and treatment result in significant harm to many patients, especially increasing the risk of suicide, the Citizens Commission on Human Right is calling on Congress to investigate in-patient psychiatric treatment,” said Anne Goedeke, president of the organization’s National Affairs Office. 

“The current standard treatment in psychiatric facilities is not only failing to decrease the rate of suicide in the U.S., but it is increasing it at a cost of human lives.  This must stop.”

Posted in Big Muddy River Newsletter, Press Releases | Tagged , , , , | Comments Off on New Research Links Psychiatric Hospitalization to Much Higher Risks of Premature Death and Suicide After Discharge, CCHR Warns

Mothers’ Psychiatric Drug Use Increases Risk of Newborns Needing Urgent Medical Attention, New Research Finds

Posted on July 1, 2024 by cchrstl

Expectant mothers considering psychiatric drugs should have the increased risks of premature birth and respiratory, circulatory, and feeding problems for their newborns fully disclosed to them by their prescribers.

by CCHR National Affairs Office

The Citizens Commission on Human Rights (CCHR), a mental health watchdog organization, is calling attention to a new study indicating the increased risks of newborns experiencing respiratory distress, circulatory distress, and feeding problems as a result of their mothers taking psychiatric drugs during pregnancy. Newborns exposed to the drugs in the womb were also more likely to have been born prematurely, researchers found. CCHR is making the research known so that expectant mothers and their prescribers can make fully informed decisions about starting or stopping the drugs. 

Observing that the use of antidepressants for depression during pregnancy has increased worldwide and that pregnant women may be taking other types of psychiatric drugs as well, German researchers set out to investigate the frequency and severity of the resulting effects on newborns from their exposure to single or multiple psychiatric drugs before birth. 

Among 207 newborns studied, nearly two out of three (62%) had clinical symptoms after birth from exposure in the womb to their mother’s psychiatric drugs. This was close to four times as many as in the control group (17%) of newborns whose mothers had not used the drugs. 

Neonatal therapy was needed for 41% of the newborns exposed to psychiatric drugs, as compared to 3% of newborns who were not exposed. It made no difference if the mothers took one or multiple psychiatric drugs or what class of psychiatric drug was used. The greater need for neonatal therapy resulted from cumulative multiple symptoms. 

One in three psychiatric drug-exposed newborns with symptoms had more than one symptom, which was six times as many as non-exposed newborns. The exposed newborns had more frequent respiratory distress, circulatory distress, hypothermia, and feeding problems than the newborns not exposed to psychiatric drugs. The exposed infants also had significantly lower scores on the Apgar scoring system used to assess newborns’ well-being immediately after birth. Mothers taking psychiatric drugs also were more than three times more likely to give birth prematurely.

“The increasingly frequent maternal drug treatment of depression and anxiety disorders in pregnancy results in an increasing number of neonates [newborns] requiring special neonatal therapy,” the researchers wrote, advising that newborns “should be continuously monitored for at least 24 hours.”

Other recent research has indicated that expectant mothers’ use of selective serotonin reuptake inhibitor (SSRI) antidepressants during pregnancy may adversely affect the brain development in their children and increase the risk of certain birth defects and miscarriage.

Tapering and discontinuation of SSRIs before and during the early phase of pregnancy was advised in another recent study of withdrawal symptoms experienced by newborns born to mothers who had taken antidepressants during pregnancy. The newborns’ withdrawal symptoms included rapid breathing, respiratory distress, tremors, and lower blood sugar.

“Expectant mothers should have the risks to their babies from taking psychiatric drugs fully disclosed by their prescribers so they can make fully informed decisions about whether to take the drugs during pregnancy,” said Anne Goedeke, president of the CCHR National Affairs Office. “Anyone who wants to stop taking a psychiatric drug is cautioned to do so only under the supervision of a physician because of potentially dangerous withdrawal symptoms.”

Posted in Big Muddy River Newsletter, Press Releases | Tagged , , , , , , , | Comments Off on Mothers’ Psychiatric Drug Use Increases Risk of Newborns Needing Urgent Medical Attention, New Research Finds

CCHR Calls Attention to New Research Finding More Serious Risks to Elderly Dementia Patients from Antipsychotic Drugs

Posted on June 24, 2024 by cchrstl

Citizens Commission on Human Rights calls for government action to make prescribers and caregivers of the elderly aware of the wider range of serious risks to dementia patients from antipsychotic drugs and to curtail the wrongful use of the drugs.

by CCHR National Affairs Office

Citizens Commission on Human Rights (CCHR) is calling attention to new research that has found a wider range of serious or life-threatening risks to elderly patients with dementia from taking antipsychotic drugs than what is currently found in drug regulatory agency warnings.  Despite previously known safety concerns, antipsychotic drugs continue to be prescribed to older adults for psychological and behavioral symptoms common to dementia.  More than two million Americans over the age of 65 are currently prescribed antipsychotic drugs.

The U.S. Food and Drug Administration (FDA) requires that all antipsychotics include a black box warning, its most serious type of warning, stating that the psychiatric drugs are associated with increased rates of stroke and death in older adults with dementia.

In a new study, researchers in the U.K. recently went beyond those two known risks, investigating 20 years of medical records for more than 200,000 patients 50 years of age and older with dementia, to look for conclusive evidence of other adverse effects from antipsychotics.  

They found that antipsychotic use was linked to “a considerably wider range of harms” for older adults with dementia than previously known and that the greatest risks of these serious or life-threatening events occurred soon after the drugs were first taken.

“Antipsychotic use compared with non-use in adults with dementia was associated with increased risks of stroke, venous thromboembolism [blood clot in a vein], myocardial infarction [heart attack], heart failure, fracture, pneumonia, and acute kidney injury,” wrote Pearl L. H. Mok, PhD, of the Centre for Pharmacoepidemiology and Drug Safety at the University of Manchester in the U.K.

Mok emphasized the importance of the findings: “The range of adverse outcomes was wider than previously highlighted in regulatory alerts, with the highest risks soon after initiation of treatment.” 

Beyond the additional safety concerns, the researchers also noted that “the efficacy of antipsychotics in the management of behavioural and psychological symptoms of dementia remains inconclusive.” 

In spite of this potentially negative risk-benefit ratio, antipsychotic prescribing in dementia treatment remains common and has even increased in recent years, Mok and colleagues write.  They suggest that further regulatory and legislative action may be needed to curtail dangerous prescribing practices.  Their study was published in the British medical journal, The BMJ.

“With the latest research showing even greater risks of very serious harm to older adults with dementia from antipsychotics, the FDA and other government agencies should take action now to make the harms more widely known and curtail the rampant prescribing of these psychiatric drugs to such a vulnerable population,” said Anne Goedeke, president of the CCHR National Affairs Office.  “Prescribers and caregivers of the elderly need to know that these drugs can put lives even more at risk than previously known.”

After investigating the practice of giving elderly nursing home patients a psychiatric diagnosis of schizophrenia as a rationale for then prescribing antipsychotic drugs, the U.S. Department of Health and Human Services (HHS) Office of the Inspector General issued a report in 2022 which disclosed that from 2015 through 2019, the number of nursing home residents reported as having schizophrenia nearly tripled (194%).

The HHS report found that, taking all classes of psychiatric drugs into account, eight in 10 nursing home residents were prescribed some type of psychiatric drug each year from 2011 to 2019.  Critics call this drugging “chemical straightjackets.”  The report found that nursing homes with stretched staffing had higher use of psychotropic drugs, suggesting the drugs were used to subdue patients to ease the workload of staff.

Following that report, the Centers for Medicare & Medicaid Services (CMS) launched its own investigation in 2023 into residents of nursing homes being falsely reported as having schizophrenia so they could be inappropriately sedated with antipsychotic drugs.

Researchers in another 2024 study examined whether overprescribing could be curtailed by warning letters sent by CMS to primary care physicians with the highest-volume prescribing of the antipsychotic drug quetiapine (Seroquel) for Medicare patients with dementia.  The result was that the warning letters significantly reduced the doctors’ antipsychotic drug prescribing, with no adverse impact on the cognitive, behavioral, or physical health of the dementia patients – more evidence of the wrongful use of these psychiatric drugs with dementia patients.

WARNING: Anyone wishing to discontinue or change the dose of an antipsychotic or other psychiatric drug is cautioned to do so only under the supervision of a physician because of potentially dangerous withdrawal symptoms.

Posted in Big Muddy River Newsletter, Press Releases | Tagged , , , , , , , | Comments Off on CCHR Calls Attention to New Research Finding More Serious Risks to Elderly Dementia Patients from Antipsychotic Drugs